Selected MAOIs/Selected Antihypertensive Agents Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, the effects of one or both medicines may increase.

What might happen:

An increase in side effects of one or both medicines may occur. Using these medicines together may cause abnormally low blood pressure.

What you should do about this interaction:

If you experience dizziness, lightheadedness, or weakness, especially upon standing, contact your doctor. If you experience these symptoms, rise slowly when changing positions from lying to standing. The dose of your medicines may need adjusting. Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Nardil (phenelzine sulfate) US prescribing information. Parke-Davis May, 2007.
  • 2.Parnate (tranylcypromine sulfate) US prescribing information. GlaxoSmithKline May, 2010.
  • 3.Remick RA, Froese C. Monoamine oxidase inhibitors: clinical review. Can Fam Physician 1990 Jun;36:1151-5.
  • 4.Razani J, White KL, White J, Simpson G, Sloane RB, Rebal R, Palmer R. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 1983 Jun;40(6):657-61.
  • 5.Tulen JH, Volkers AC, van den Broek WW, Bruijn JA. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression. J Clin Psychopharmacol 2006 Oct; 26(5):542-4.